News
NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended regulators approve Servier's IDH1/2 inhibitor Voranigo (vorasidenib) as a treatment for ...
Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to cross the blood-brain barrier.
The Medicines and Healthcare Products Regulatory Agency said it will closely track adverse events associated with the treatment.
The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results